Filing Flows › Pelthos Therapeutics (PTHS) › Takeover & LBO
Is Pelthos Therapeutics (PTHS) a takeover target?
A leveraged buyout does not work for Pelthos Therapeutics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-11-03): LIGAND PHARMACEUTICALS INC (49.9%): The Merger Agreement. On October 30, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Credit Card Merger Sub, Inc., a Delaware corporation and a wholly owned.
Why a leveraged buyout does not fit
The buyout model needs Pelthos Therapeutics' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-11-03 · 13D · LIGAND PHARMACEUTICALS INC (49.9%): The Merger Agreement. On October 30, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Credit Card Merger Sub, Inc., a Delaware corporation and a wholly owned
- 2026-10-30 · 8-K deal · Pelthos Therapeutics to Combine with Castle Creek Biosciences, Creating Transformative Biotechnology Company Focused on Serious Diseases that Affect the Skin
Pelthos Therapeutics' latest quarter
Pelthos Therapeutics, Q2 2026: revenue $15.6M, operating margin -111.0%, net loss $23.4M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Questions
Is Pelthos Therapeutics being acquired?
The latest signal on file is from 2026-11-03: LIGAND PHARMACEUTICALS INC (49.9%): The Merger Agreement. On October 30, 2026, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Credit Card Merger Sub, Inc., a Delaware corporation and a wholly owned. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Pelthos Therapeutics?
A leveraged buyout does not work for Pelthos Therapeutics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.